Ascendis Pharma (ASND) Q1 2026 earnings review
YORVIPATH Drives Profitability, But Top-Line Stalls Sequentially
Ascendis Pharma reached a massive milestone in Q1 2026, Reversing its historical operating losses to achieve a 22.4% Non-IFRS operating margin. This was overwhelmingly driven by YORVIPATH, which saw revenue surge 340% YoY to €197 million. However, the sequential story is less rosy: total revenue was flat QoQ (€247M vs €248M in 25Q4) because the legacy SKYTROFA business is abruptly Decelerating, shrinking 14% YoY. A staggering €679 million tax asset recognition artificially inflated GAAP EPS to €9.75, obscuring a cleaner Non-IFRS net profit of €18 million. With YUVIWEL approved and a massive $575 million convertible debt overhang cleared post-quarter, the balance sheet is pristine, but the company must prove SKYTROFA's decline isn't structural.
🐂 Bull Case
Non-IFRS operating margin swung from -77.9% a year ago to +22.4%. Ascendis has transitioned from a cash-burning biotech into a self-sustaining commercial entity.
Subsequent to Q1, the company wiped €733M in derivative and convertible note liabilities off the books via equity conversion and raised $187.5M in non-dilutive cash by selling a Priority Review Voucher.
🐻 Bear Case
The legacy growth hormone franchise is contracting (-14% YoY), dragging down total company QoQ growth to flat despite YORVIPATH's strong uptake.
The abrupt discontinuation of the internal Oncology pipeline means significant historical R&D spend will not yield internal commercial returns, forcing reliance entirely on the endocrinology portfolio.
⚖️ Verdict: 🟢
Bullish. The overarching thesis of the TransCon platform yielding highly profitable blockbusters is intact. While SKYTROFA's decline is a blemish, the combination of YORVIPATH's scale, YUVIWEL's launch, and the elimination of the 2028 convertible debt vastly outweighs the negatives.
Key Themes
YORVIPATH Trajectory Remains Accelerating YoY
YORVIPATH generated €197M in Q1, up 340% YoY. The U.S. launch continues to capture share with over 1,000 new patient enrollments in the quarter and over 6,300 total since launch. The drug's scale is now large enough to single-handedly pull the entire company into operating profitability.
YUVIWEL Clears FDA, Initiates Third Revenue Stream
The FDA granted accelerated approval for YUVIWEL (TransCon CNP) for achondroplasia, securing orphan drug exclusivity through 2033. Early uptake is promising with over 60 unique enrollments by May 1. This diversifies the revenue base and validates the TransCon platform's repeatability.
Unprecedented Tech Innovation in COACH Trial
The Week 52 data from the Phase 2 COACH Trial (TransCon CNP + TransCon hGH) represents a major technological breakthrough. The combination therapy pushed mean annualized growth velocity past the 97th percentile of average stature children. Furthermore, it demonstrated unprecedented improvements in arm span and lower limb alignment compared to monotherapy, cementing Ascendis' scientific moat.
SKYTROFA Contradicts 'Fundamental Pillar' Narrative
In previous quarters, management repeatedly touted SKYTROFA as a 'fundamental pillar' and guided that revenue would track prescription growth. However, 26Q1 data completely contradicts this: revenue fell to €44M, a 14% Decelerating YoY decline. If this is driven by competitive pressure rather than mere seasonality, a core leg of the 'Vision 2030' target is wobbly.
YORVIPATH QoQ Growth is Decelerating
While YoY growth is stellar, sequential growth is cooling rapidly. YORVIPATH added €40M QoQ in Q3, €44M QoQ in Q4, but only €10M QoQ in Q1 (€187M to €197M). Management cited 'normal seasonality and the temporary impact of additional patients supported by free drug', but this suggests the initial pent-up demand bolus is clearing and growth rates are normalizing.
Oncology Surrender Narrows the Pipeline
Despite claiming TransCon IL-2 beta/gamma demonstrated improved median overall survival (10 months vs 6-7 months historical), Ascendis completely discontinued internal development. While tactically prudent to protect margins, this means the company failed to diversify outside of rare endocrinology and writes off years of R&D investment.
Macro-Level Free Drug and Access Seasonality
The company explicitly noted that Q1 revenue for YORVIPATH in the U.S. was temporarily impacted by patients supported by free drug programs and normal Q1 insurance deductible resets. In Europe, a one-time positive impact occurred due to expanded market access. These friction points in payer dynamics remain a structural industry headwind.
Other KPIs
Massively inflated by a one-time accounting maneuver: the recognition of €679 million in previously unrecognized deferred tax assets. Investors must strip this out to view the underlying business. The Non-IFRS net profit of €18 million provides the true picture of the company's operating turnaround.
On May 6, 2026, Ascendis forced the conversion of all its outstanding 2.25% convertible notes due 2028. This settled €733 million in current liabilities (borrowings and derivatives) in exchange for 3.63 million ordinary shares. This brilliant structural move totally cleans the balance sheet and removes near-term refinancing risk.
Stable. Up slightly YoY from €188 million in 25Q1, but tightly controlled considering the ongoing global commercial rollout of YORVIPATH and the launch preparation for YUVIWEL. R&D actually dropped from €87M to €59M, funding the SG&A increase.
Guidance
Management anticipates a regulatory decision from the European Medicines Agency for achondroplasia in the fourth quarter, paving the way for EU commercialization following the US launch.
Ascendis expects interim 78-week data in the upcoming quarter, providing further validation of the combination therapy's durability and long-term safety profile.
Key Questions
SKYTROFA Demand Dynamics
SKYTROFA sales dropped 14% YoY in Q1 to €44M. Was this entirely driven by seasonal gross-to-net adjustments and copay assistance, or are you seeing structural volume and pricing pressure from competitors?
YORVIPATH Free Drug Impact
You cited 'additional patients supported by free drug' acting as a temporary impact on Q1 YORVIPATH revenue. Can you quantify this margin drag and outline the timeline for converting these specific patients to commercial reimbursement?
Oncology Monetization
With the internal discontinuation of the TransCon IL-2 beta/gamma program despite positive OS data, what specific strategic alternatives (out-licensing, spin-off) are you exploring, and what is the timeframe for monetizing this asset?